Carsten Reinhardt

Carsten has extensive experience in translational development. He has progressed multiple biological compounds for oncology and immunology diseases, spanning early preclinical development through first-in-man studies, to approvals in the US and Europe.

He is a member of the American Society of Clinical Oncology, the American Society of Hematology, the Association for Cancer Immunotherapy as well as of the European Society of Medical Oncology, and is Visiting Professor for Pharmaceutical Medicine at the University of Basel. Previously, as International Medical Leader at Hoffmann-La Roche (Basel, Switzerland), Carsten had global responsibility for the development of Herceptin®.

Carsten received a Medical Degree in 1993 from the University of Munich, Germany. In addition, he completed a Ph.D. thesis in Cellular Immunology at the Ludwig-Maximilians Universität München in Munich, Germany (summa cum laude).